Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus

Atherosclerosis

Volumn 120, Issue 1-2, 1996, Pages 7-14

  Morishita, Eriko ^a   Asakura, Hidesaku ^a   Jokaji, Hiroshi ^a   Saito, Masanori ^a   Uotani, Chika ^a   Kumabashiri, Ichiro ^a   Yamazaki, Masahide ^a   Aoshima, Keiji ^a   Hashimoto, Takuma ^a   Matsuda, Tamotsu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Coronary heart disease; Diabetes mellitus; Fibrinogen; Lipoprotein(a); Plasminogen activator inhibitor 1; Thrombin antithrombin III complex

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0030070114     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05647-5     Document Type: Article

References (34)

1. Assman G, Shulte H. The Prospective Cardiovascular Munster (PROCAM) Study: Prevalence of hyperlipidemia in persons with hypertension and diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713.
2. Garcia Frade LJ, De La Galle H, Alva I, Navano JL, Creighton LJ, Gaffney PJ. Diabetes mellitus as a hypercoagulable state: It's relationship with fibrin fragments and vascular damage. Thromb Res 1987;47:533.
3. Armstrong VW, Cremer P, Eberle E, Manke A, Shulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249.
4. Rath M, Neindorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579.
5. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombolic risks associated with lipoprotein(a). Nature 1989;339:301.
6. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132.
7. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:01.
8. Clauss A. Gerinnungs physiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957;17:237.
9. Kennel WB, D'Agostin RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672.
10. De Feo P, Gaisano MG, Haimond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest 1991;88:833.
11. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533.
12. Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetes Med 1991;8:898.
13. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988:8:68.
14. Rydzewski A, Kawamura H, Watanabe I, Takada T, Takada A. Plasminogen activators and plasminogen activator inhibitor (PAI-1) in type II diabetes mellitus. Fibrinolysis 1990;4:183.
15. Grant MB, Fitzgerald C, Guay C, Lottenberg R. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus. Metabolism 1989;38:901.
16. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Correlation between fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986;35:250.
17. Juhan-Vague I, Roui C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients relationship with plasma insulin. Thromb Haemost 1989;61:370.
18. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease by hyperinsulinemic states. Proc Natl Acad Sci USA 1991;88:9959.
19. Emeis JJ, Kooistni T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986;163:1260.
20. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells. Atherosclerosis 1990;10:1067.
21. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein(a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 1992;117:42.
22. Heller FR, Galanti L, Jamart J, Parfonry A, Honore P, Hondekijin J-C, Derue G, Buysschaert M, Novik V. Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 1993;16:819.
23. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein(a) in man. J Clin Invest 1980;65:1483.
24. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM. 5′ control region of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA 1993;90:1369.
25. Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P, Doumith R, Thervet F, De Gennes JL. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. J Am Med Assoc 1990;263:36.
26. Haffner SM, Tuttle KR, Rainwater DL. Lack of change of Lp(a) concentration with improved of glycemic control in subjects with type II diabetes. Metabolism 1992;41:116.
27. Taskinen MR, Enholm C, Jaubianen M, Kauppinen-Makelin R, Yki-Larvinen H. FINMIS group: the concentration of Lp(a) is not influenced by the degree of glycemic control in NIDDM (abstract). 9th International Symposium on Atherosclerosis, Rosemont, IL, 1991;196.
28. Haffner SM, Klein BEK, Moss SE, Klein R. Lack of association between Lp(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Survey of Diabetic Retinopathy. Metabolism 1992;41:194.
29. Velho G, Cohen D, Erlich D, Froguel P, Turpin E, Passa P, Neel D. Lipoprotein(a) in diabetic patients and normo-glycemic relatives in familial NIDDM. Diabetes Care 1993;16:742.
30. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985;57:293.
31. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetylcysteine. Lancet 1991;337:203.
32. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. J Am Med Assoc 1990;264:723.
33. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipo-protein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303.
34. 2-antiplasmin. Biochem J 1992;286:79.